Liver cancers are highly heterogeneous with poor prognosis and drug response. A better understanding between genetic alterations and drug responses would facilitate precision treatment for liver cancers. To characterize the landscape of pharmacogenomic interactions in liver cancers, we developed a protocol to establish human liver cancer cell models at a success rate of around 50% and generated the Liver Cancer Model Repository (LIMORE) with 81 cell models. LIMORE represented genomic and transcriptomic heterogeneity of primary cancers. Interrogation of the pharmacogenomic landscape of LIMORE discovered unexplored gene-drug associations, including synthetic lethalities to prevalent alterations in liver cancers. Moreover, predictive biomarker candidates were suggested for the selection of sorafenib-responding patients. LIMORE provides a rich resource facilitating drug discovery in liver cancers. Qiu et al. establish the Liver Cancer Model Repository, combining public and newly generated cell lines, which represents genomic and transcriptomic heterogeneity of Eastern Asian hepatocellular carcinomas, and use it to reveal gene-drug associations and potential biomarkers for selecting sorafenib-responding patients.
- liver cancer
- patient-derived cancer models
ASJC Scopus subject areas
- Cancer Research